AT base pairs, so that hybridization becomes purely a function of the length of the oligunucleotide (8 by Sell and Monnier (1) in the human dura mater collagen, is a bifunctional condensation product of arginine, lysine, and ribose, and is formed through the Maillard reaction. Recent studies reveal that pentosidine accumulates in human tissues with age and that its formation is affected by the acceleration of this process in uremic and diabetic conditions (2, 3). Although several researchers have investigated the amount of pentosidine in tissues, until recently only one study has dealt with pentosidine in body fluids. Odetti et al. (4) developed a combined reversed-phase ion-exchange HPLC method to quantify pentosidine in a hydrolysate of serum and reported that serum pentosidine was increased in diabetes and extremely high in uremia. However, their method is complex, requiring two HPLC systems, and the procedures are tedious. Previously, we developed a method to quantify pentosidine in hydrolysates of human urine, using SP-Sephadex C-25 pretreatment before HPLC, and found that urinary pentosidine increased exponentially with age in healthy subjects (5). In the present study, we applied this method to serum and quantified the pentosidine in serum from control and uremic subjects. Seven of these patients were diabetic. For a control groUp, serum samples were obtained from 33 healthy subjects, ages 18 to 57 years, with no history of renal disease or diabetes
phaseHPLC, we developeda method for quantifying pentosidine in the acid hrolysate of serum.We examinedconcentrationsof pentosidinein serum from 98 patients with end-stagerenaldisease requinng hemodialysisand from 33 normalcontrolsubjects. The mean (± SD) concentration of pentosidine was significantly greater in serum from uremic patientsthan that from control subjects (1267 ± 695 nmol/L vs 77 ± 40 nmol/L, P = 0.0001). There was a significant correlation betweenserum pentosidine concentrations and age in control subjects (r = 0.453, P <0.01), but not in are tedious. Previously, we developed a method to quantify pentosidine in hydrolysates of human urine, using SP-Sephadex C-25 pretreatment before HPLC, and found that urinary pentosidine increased exponentially with age in healthy subjects (5) . In the present study, we applied this method to serum and quantified the pentosidine in serum from control and uremic subjects. Pentosidine was isolated from human articular cartilage. Methods for purification and characterization are described elsewhere (6). ' 
Subjects and Methods

Subjects
Resufts
Assay Procedures Figure 1 shows the chromatograins of serum samples in several conditions. Pentosidine was not detected in the supernates of sera from control subjects after precipitation with 50 g/L PCA. However, it was detected in low concentrations in the PCA supernates of sera from uremic patients. Pentosidine was also detected in the PCA residues of sera from both control subjects and uremic patients. ± SD, 4.7% ± 1.6%) in the uremic patients (n = 12) . The right-hand panels of Figure 1 show chromatograrns of the serum hydrolysates without precipitation by PCA. There was almost no difference between hydrolysates of serum with precipitation by PCA and without precipitation, although the peak for pentosidine in the hydrolysate without precipitation by PCA was larger than that with precipitation. Therefore, we directly hydrolyzed serum without precipitation for further studies of quantification of pentosidine in serum from control subjects and uremic patients.
A calibration line was constructed by assaying seven serum standards generated by adding 40 pmol-4 nmol of pentosidine to 0.5 mL of serum from a healthy subject.
Linear-regression analysis showed the linearity of the calibration curve (r = 0.999). The analytical recovery of added pentosidine was 95.5% (SD 2.9%) at 500 nmol/L, with similar recovery at 50 nmol/L (n = 5 each). The intraassay CV was 3.6% (n = 5) and the interassay CV 
Clinical Studies
The concentrations of pentosidine in serum from control subjects and uremic patients are shown in Figure 2 . In uremic patients, serum pentosidine weakly but significantly increased with the duration of hemodialysis (r = 0.272, P <0.05) (Figure 4 ).
DIscussion
Pentosidine was not detected in the PCA supernates of sera from control subjects. This indicates that most pentosidine is protein-bound in serum in healthy subjects. Because we could detect pentosidine in the PCA supernates of sera from uremic patients, both free pentosidine and protein-bound pentosidine may increase in uremic patients.
We previously observed (7) that 80-90% of pentosidine is present in the free form in urine from normal subjects and diabetic patients, the amount of urinary excretion being about 29 g (77 nmol) per day in the normal subjects. Therefore, protein-bound pentosidine in serum is probably catabolized to free pentosidine and excreted in urine. If pentosidine is a nonthreshold substance for glomerular filtration in the kidney and if the normal value for pentosidine clearance is >100 mL/min (8) , the concentration of free pentosidine in serum should be <0.5 nmol/L (77 nmol/1440 mm divided by 100 mldmin). This concentration (0.5 nmol/L) corresponds to 0.025 pmol per injection in our method described above. Because this amount of pentosidine is below the detection limit of our method (-0.2 pmol per injection), we were unable to investigate the origin of the free pentosidine in urine. The correlationbetween pentosidine and age in control subjectsimpliesthat the formation of pentosidinein serum increases with age. However, in uremic patients requiring hemodialysis, we saw no significant correlation between pentosidine and age but found a significant correlation between pentosidine and the duration of hemodialysis treatment.
Apparently, the effect of uremia on the accumulation of pentosidine in serum is greater than the effect of aging.
We also saw no difference in serum pentosidine concentrations between diabetic and nondiabetic uremic patients. However, the number of diabetic patients was few and the hemodialysis treatment of diabetic patients was shorter than for nondiabetic patients (mean, 58.5 vs 110.3 months, respectively).
